Stefania Vallone, LuCE president, spoke to Health Europe Quaterly about the disparities and barriers that remain in access to innovative lung cancer diagnostics, drugs, and services. The main topics were: the key barriers to faster access to treatment, diagnostic an care in Europe; how financial pressure and high costs of new drugs impact should be addressed; how important are clinical trials for lung cancer patients. You can read the interview here http://bit.ly/2GuBHnz.